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The discovery of CD117 mutation in almost all gastrointestinal stromal tumors (GISTs) marked a milestone. Other
spindle cell neoplasms arising from the GI tract including lipoma, schwannoma, hemangioma, leiomyoma, and
leiomyosarcoma are typically CD117-negative. GIST research and clinical care now represent a paradigm of
translating discoveries in the molecular pathogenesis of cancer into highly effective targeted therapies that
selectively inhibit etiologic “driver” pathways, leading to dramatically improved clinical outcomes. A series of
investigations and trials are underway to develop novel and effective ways to treat patients with GIST. In this review,
we discuss the highlights of recent advances and novel agents for GIST therapy.Introduction
Remarkable developments have occurred in gastrointes-
tinal stromal tumor (GIST) research and clinical care in
the past several years. GIST has served as a model for
translational therapeutics in solid tumors. A major
breakthrough occurred with the discovery of expression
of the CD117 antigen by almost all GISTs. Other spindle
cell neoplasms arising from the gastrointestinal (GI) tract
including lipoma, schwannoma, hemangioma, leio-
myoma, and leiomyosarcoma, are typically CD117-nega-
tive [1]. The CD117 molecule is part of the KIT (c-kit)
receptor tyrosine kinase (KIT RTK) encoded by the KIT
proto-oncogene (Figure 1). Since CD117 was found to be
associated with GIST, the estimated incidence of GIST
has been revised upward to approximately 5,000 new
cases per year in the United States (US) [2,3].
Molecular signature of GIST
In 1998, Hirota et al. defined the relationship between
GIST and certain mutations in the KIT proto-oncogene
that conferred uncontrolled activation to the KIT signaling
enzyme [4]. Importantly, almost all GIST lesions with mu-
tant KIT demonstrate only a single site of mutation in the
KIT gene (Figure 2). Complex genetic changes are rare at
initial diagnosis. Gain-of-function mutations have been
recognized most commonly (up to 70% of cases) in exon
11 of KIT. Approximately 15% of GIST patients do not* Correspondence: delong_liu@nymc.edu
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reproduction in any medium, provided the ordemonstrate activation and aberrant signaling of the KIT
receptor. An additional 10% harbor mutations in the plate-
let-derived growth factor receptor – alpha (PDGFRA)
[5,6]. Very rare cases may have mutations in the BRAF
kinase [7,8]. Overall, about 5% of GISTs have no detectable
kinase mutations (and are often referred to as wild type
GIST). Janeway and colleagues have also shown that germ-
line mutation in succinate dehydrogenase subunits B, C or
D can cause KIT-/PDGFRA- wild type GIST [9].
National Comprehensive Cancer Network (NCCN)
guidelines recommend KIT immunostaining for all cases
of suspected GIST, and if negative, mutational analysis
[10,11]. Routine genotyping of KIT-positive GISTs is not
recommended.
Imatinib for metastatic, unresectable or recurrent
GIST
Imatinib was found to be able to potently inhibit the tyrosine
kinase activity of KIT. The United States (US)–Finland trial
enrolled 147 patients with metastatic GIST between July
2000 and April 2001 [12]. Nearly concurrently, a dose-find-
ing study was also begun in Europe under the auspices of
the European Organization for Research and Treatment of
Cancer (EORTC) Sarcoma Group to assess the tolerability
and potential activity [13]. The two studies confirmed the
unparalleled activity of imatinib in controlling metastatic
GIST. The median overall survival (OS) of advanced GIST
patients increased from 18 to 57 months with imatinib ther-
apy [14]. Despite these excellent results complete responses
(CR) are rare (less than 10 percent), and most patients whoLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 KIT (CD117) receptor tyrosine kinase structure and
common mutations found in gastrointestinal stromal tumor.
Arrows indicate the corresponding mutations in the exons.
Figure 2 KIT (CD117) gene structure and common mutations in
gastrointestinal stromal tumor. Arrows indicate the positions of
common mutations in the KIT gene.
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mutations in KIT. The median time to progression is
roughly two to three years [12,15-17], although it is longer in
some series [18]. Factors influencing the duration of disease
control are still not well understood [17].
Correlative studies have reported differences in the activity
of imatinib based on the genotype of the GIST lesion. The
mutations in KIT and PDGFRA correlate with clinical re-
sponse [19-22]. In a report of 127 patients with GISTs re-
ceiving imatinib, activating mutations in KIT and PDGFRA
were found in 88 and 4.7 per cent, respectively [19]. All of
the KIT mutant isoforms were associated with a response,
however only a subset of PDGFRA mutants were imatinib-
sensitive. Among patients with KIT mutations, those with
an exon 11 mutation had a significantly greater response rate
compared to patients with an exon 9 mutation or no detect-
able mutation in KIT or PDGFRA (84 versus 48 and 0 per
cent, respectively). Exon 11 mutation patients also exhibited
a longer time to treatment failure. A US Intergroup trial sub-
sequently confirmed these results. This trial enrolled 324
patients and compared the two doses of imatinib [22].
Patients whose tumors who had an exon 11 mutant isoform
were more likely to have an objective response to imatinib
than those with an exon 9 isoform or those who had no
mutations (72 versus 44 and 45 per cent, respectively).
Patients with an exon 11 mutation also had a significantly
longer time to disease progression (25 versus 17 and
13 months, respectively) and OS (median 60 versus 38 and
49 months, respectively). This also translated into more dur-
able disease control over time with continuous dosing of
imatinib. The results of this trial as well as subset analysis
from the randomized EORTC dose–response trial suggest
that high dose imatinib may preferentially benefit patients
with an exon 9 mutation [22,23]. In the EORTC trial, GISTs
of 58 patients expressed an exon 9 mutant KIT protein. An
initial daily imatinib dose of 800 mg resulted in a signifi-
cantly superior progression-free survival (hazard ratio forprogression 0.39) compared to 400 mg/day. In contrast, the
time to progression was not affected by the initial dose in
patients with an exon 11 mutation or wild-type KIT. No cor-
responding differences in overall survival between low-dose
and high-dose initial therapy in patients with exon 9 muta-
tions was seen. Similar conclusions were also reached in a
meta-analysis that included patients treated on the EORTC
and the US Intergroup trial [24]. Imatinib-sensitive PDGFRA
mutations explain responses in certain GIST patients with
wild-type KIT [19]. Thus, GIST lesion genotype is an im-
portant predictive tool and correlates with clinical efficacy of
imatinib as a first-line therapy. In one large series of 289
GISTs with PDGFRA mutations, 181 (63 percent) had the
imatinib-resistant substitution D842V. Because of the vari-
ability in response, patients with advanced GISTs should not
be denied a trial of imatinib if they are KIT-negative. NCCN
guidelines recommend initiating therapy for unresectable or
metastatic disease with imatinib 400 mg daily [11]. However,
if molecular diagnosis is available and the patient is exon 9-
positive, they support the use of imatinib at 800 mg daily. In
contrast, European Society for Medical Oncology recom-
mends mutation testing for all patients and starting imatinib
at 800 mg daily for exon 9 mutants [25].
Tyrosine kinase inhibitor (TKI) therapy does not ap-
pear to cure patients with metastatic GIST. Rapid disease
progression was seen within months after the imatinib is
stopped [26,27], this is considered a lifelong therapy. A
French trial randomly assigned patients with advanced
GIST and no disease progression after one year of imati-
nib to continuous treatment or interruption until disease
progression [26]. The study was stopped prematurely
after only 58 patients had been randomized when it be-
came clear that the risk of progression was significantly
higher if therapy was interrupted, even in completely
responding patients.
At the 2011 annual meeting of American Society of
Clinical Oncology (ASCO), A Le Cesne et reported the
effect of interruption of imatinib therapy in patients with
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were randomly assigned to either interrupt or continue
therapy with imatinib after 1, 3, and 5 yrs. Progression
free survival was significantly lower in the patients that
interrupted therapy as compared to the patients who
continued therapy. Imatinib re-introduction allowed
tumor control in 94% patients with interrupted treat-
ment. There was no significant difference in time to sec-
ondary resistance or OS between both arms. At the same
meeting, Domont et al. reported the influence of imati-
nib interruption and re-introduction on tumor burden in
patients with GIST on the BFR 14 trial [29]. They found
that imatinib interruption in responding patients with
advanced GIST results in tumor progression even in
patients who were in complete remission at randomization.
Among patients with imatinib interruption 49% experi-
enced progressive disease while 51% had new lesions
with concomitant progression of known lesions. Thus,
continuous therapy until disease progression (or lifelong
if disease does not progress) is currently standard of
care. These clinical data support the hypothesis that
continuous and chronic exposure to imatinib is neces-
sary to maintain control over a population of GIST cells
that may remain quiescent in the long term as long as
aberrant KIT signaling is inhibited. Future studies are
required to assess whether periodic pulse therapy might
suppress emergence of multidrug-resistant GIST clones.
TKIs for imatinib-resistant GIST
Primary resistance was seen in 12 percent of 934 patients in
the randomized European trial exploring two different
doses of imatinib and was more likely in patients with lung
but not liver metastases (41 percent) [16]. Alternatively,
clonal evolution of resistant GIST may be detected after a
durable objective response and disease control. Several
mechanisms of resistance to imatinib in GIST have been
explained [30,31]. Pharmacokinetic variability may also con-
tribute to acquired drug resistance [32]. Limited clonal pro-
gression appears as the first sign of resistance to imatinibTable 1 TKIs for imatinib-resistant GIST
Study Drug Disease Clinical Trial Nu
pa
Sunitinib Imatinib-resistant Phase 3 312
Sorafenib Imatinib- and Sunitinib resistant Phase 2 38
Nilotinib Imatinib- and Sunitinib resistant Phase 3
( ENEST g3)
248
Sorafenib Imatinib- and Sunitinib resistant Phase 2 41
Dasatinib Imatinib- and Sunitinib resistant Phase 1 47
Abbreviations: TTP time to progression; ORR overall response rate; PR partial respon[31,33,34]. The mechanism of resistance to imatinib most
commonly observed is the emergence of new secondary
mutations [30,31]. Another likely mechanism is that pre-
existing double-mutant tumor cells slowly grow out under
the influence of chronic imatinib selection pressure, similar
to the antibiotic-resistant strains of bacterial pathogens.
Dose escalation of imatinib can also be considered in resist-
ant patients started on imatinib 400 mg daily. The efficacy
of this approach was shown in follow-up reports from both
the American and European randomized dose-finding stud-
ies [14,35].
Sunitinib is an anti-angiogenesis agent by virtue of tar-
geting multiple tyrosine kinases, including the vascular
endothelial growth factor receptors (VEGFR) in addition
to PDGFR [22,36-38]. An international phase III trial of
sunitinib versus placebo in 312 patients with refractory
disease definitively established the role of sunitinib in
this setting [38] (Table 1). Patients demonstrating pro-
gression while on placebo crossed over to the active
treatment arm. Despite a low objective response rate in
the sunitinib group (7 percent partial response), median
time to tumor progression, the primary endpoint, was
fourfold longer as compared to the placebo group (27
versus 6 weeks). Despite the crossover, survival was also
significantly better with initial sunitinib. Based on these
data, this agent was approved for treatment of GIST fol-
lowing failure of imatinib in January 2006.
Clinical benefit (partial response or stable disease for
longer than six months) was significantly higher for
those with a primary KIT exon 9 (58 percent) or wild-
type KIT/PDGFRA mutation (56 percent) than for those
with a KIT exon 11 mutation (34 percent). The same
pattern was seen for progression-free survival (PFS) and
OS. Following progression on imatinib, patients with
KIT exon 9 mutation or a PDGFRA mutation had a me-
dian time to progression of 19 months, while for those
with exon 11 mutations, it was only 5 months. There
was also a correlation between secondary mutations and
response to sunitinib. Both progression-free and overallmber of
tients
Results Status Reference
TTP 27 weeks FDA Approved. On
NCCN guidelines.
[38]




ORR 37.6% On NCCN
guidelines.
[41]
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ondary KIT exon 13 or 14 mutations than for those with
exon 17 or 18 mutations (7.8 versus 2.3 months). Resist-
ance to sunitinib shares similar pathogenetic mechan-
isms to those identified in imatinib failure, with
acquisition of secondary mutations after an extended ini-
tial response [43].
Limited data are available on the efficacy of sorafenib
and other TKIs (i.e., dasatinib, motesanib, nilotinib) in
refractory GIST or after resistance to imatinib and/or
sunitinib [44-49]. The efficacy of sorafenib was addressed
in a multicenter phase II trial involving patients with re-
fractory GIST [50]. In a report presented at the 2011
ASCO GI Cancers symposium, the disease control rate
was 68 percent, and median PFS was 5.2 months. The
most common grade 3 toxicities were hand-foot syn-
drome and hypertension. Kindler and co-workers
reported the final results at the 2011 ASCO Annual
Meeting [39]. Thirty eight patients were enrolled with
baseline mutations in exon 11 (65%), exon 9 (15%),
PDGFRA (4%). They reported partial responses in 13%
and stable disease in 55%. The median PFS was
5.2 months and OS was 11.6 months. Grade 3 and 4
toxicities included hand-foot syndrome (45%), hyperten-
sion (21%), diarrhea (8%), hypophosphatemia (8%), GI
bleed (5%), thrombosis (3%), GI perforation (3%) and
intracranial hemorrhage (3%).
Korean GIST Study Group (KGSG) reported the results
of a prospective, multicenter, phase II study evaluating the
efficacy and safety of sorafenib in patients with advanced
GISTs who failed previous standard TKI’s [41]. Thirty-one
patients with pathologically proven metastatic or unresect-
able GISTs who failed both imatinib and sunitinib were
accrued. Ten patients received nilotinib as a third line
treatment. With sorafenib, 3 patients (10%) achieved a par-
tial response and 17 patients (55%) had stable disease. The
median PFS was 4.9 months and the disease control rate
was 37.6% at 6 months. Patients with prior use of 3rd line
nilotinib and primary genotypes other than mutations at
KIT exon 11 showed significantly worse PFS.Table 2 New TKIs for GIST




day 1–21 of 28
day cycle.
Masitinib First line therapy 7.5 mg/kg/day
Crenolanib Selective for D842V
mutation
-
PTK787/ZK222584 Imatinib resistant 1,250 mg o.d
AMG 706 Imatinib-resistant 600 mg daily
Abbreviations:SD stable disease; PFS progression free survival; ORR overall responseGuidelines from the NCCN suggest sorafenib as an op-
tion for patients with imatinib and sunitinib-resistant
GIST [11]. Emerging results from in vitro studies suggest
that the choice of salvage therapy in imatinib-refractory
GISTs might depend, at least in part, on the specific mu-
tation responsible for the acquisition of resistance [51].
However, these data require validation before they can
be applied to clinical practice.
Nilotinib was studied in a randomized phase 3 clinical
trial (ENEST g3) [40]. In this trial nilotinib was compared
to a heterogeneous control arm in patients advanced/
metastatic GIST who had failed imatinib and sunitinib.
The control arm included best supportive care with phys-
ician choice to continue or stop imatinib or sunitinib. It
failed to show significant benefit for nilotinib.
Dasatinib is an oral tyrosine kinase inhibitor of KIT,
PDGFR, ABL and SRC with a distinct binding affinity for
KIT and PDGFR. Trent and associates reported a phase
II trial to assess antitumor activity of dasatinib in
patients with advanced GIST who were refractory to
imatinib and sunitinib [42]. They reported a partial re-
sponse (PR) rate of 32% (15/47) by Choi criteria and 21%
patients (10/47) were progression-free after 6 months.
Median PFS and OS were 2.0 months and 19 months
with median PFS for wild type GIST patients of
8.4 months. Dasatinib has significant activity but did not
meet the predefined 6 month PFS rate of 30%.
Recent advances and meeting updates
Several clinical trials are already in progress using next-
generation agents that target the KIT receptor via differ-
ent mechanisms or that target the alternate pathways.
We will now review the highlights on GIST from the
2011 American Society of Clinical Oncology (ASCO)
meeting and the 2011 ASCO – Gastro-intestinal cancers
symposium (Table 2).
New TKIs
Regorafenib is a novel oral multi-kinase inhibitor which





Phase 2 33 SD 86% [52]
Phase 2 30 PFS 41 m [53]




Phase 2 15 ORR 67% [44]
Phase 2 138 ORR33% [48]
rate.
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center phase II trial of regorafenib in patients with
advanced GIST after prior therapy with at least imatinib
and sunitinib [52]. Thirty three patients received at least
one dose of study drug. Most common grade 3 treatment
related toxicities were hypertension, hand-foot skin reac-
tion, and hypophosphatemia. There were two grade 4
events, one hyperuricemia and one thrombosis. Most eli-
gible patients were without disease progression after 4
cycles of regorafenib. Benefit was seen in patients whose
tumors had primary KIT exon 11 mutations, KIT exon 9
mutations or wild type kinase genotype. Thus, regorafe-
nib demonstrated significant activity in patients with
advanced GIST previously treated with imatinib and
sunitinib. An international phase III trial is currently
underway in patients with advanced GIST following
treatment with at least imatinib and sunitinib.
Masitinib is a new tyrosine kinase inhibitor which has a
greater activity and selectivity than imatinib. It is an oral in-
hibitor of both the KIT and PDGFRA receptors. It may have
greater activity than imatinib against wild-type GIST and
juxta-membrane KIT mutants. Blay et al. evaluated the
safety and efficacy of masitinib as a first line therapy in
patients with imatinib-naïve, inoperable, locally advanced or
metastatic GIST [53,55]. They reported a PFS of 41 months.
OS was 72% at the end of 4 years. Main toxicities were rash
(10%), neutropenia (7%) and abdominal pain (7%). A phase 3
trial is currently underway and actively recruiting partici-
pants (ClinicalTrials.gov identifier: NCT00812240).
Crenolanib (formerly CP-868596) is an orally bioavailable,
highly potent and selective PDGFR TKI for the D842V mu-
tation encoded by exon 18. Currently approved TKIs have
little to no in vitro activity against this mutation and are thus
clinically ineffective. Phase I trials of Crenolanib have shown
a favorable toxicity profile, and achievable serum concentra-
tions as high as 2,000 nanomolar [56]. At the recommended
phase II dosage (ie, 100 mg twice daily with food), theTable 3 Novel agents for GIST
Study Drug Class of Drug Disease Dosage
Everolimus mTOR inhibitor TKI resistant Everolimus 2.5 mg
with Imatinib
Everolimus mTOR inhibitor Refractory GIST 10 mg/day




Ganetespib Hsp90 inhibitor Following failure of
prior therapy
200 mg/m2 IV qwe
wks of a 28 day cy
Retaspimycin
(IPI 504)
Hsp90 inhibitor Following failure of
TKIs
400 mg/m2 weekly
doses in 21-day cy
Perifosine Akt pathway
inhibitor
Imatinib-resistant 2 doses of perifosin
daily or 900 mg qw
with daily imatnib
Abbreviations: SD stable disease; PFS progression free survival; ORR overall responsesteady-state serum concentrations were more than 16 nano-
grams/milliliter. The half life was in the range of 12.3 to 18.5
hours. Heinrich and associates reported on the effect of cre-
nolanib on phosphorylation of the imatinib-resistant D842V
PDGFRA activating mutation [54]. Mutant PDGFRα iso-
forms were expressed by transient transfection of Chinese
hamster ovary cells and these transfected cells were treated
with various concentrations of crenolanib or imatinib. Cre-
nolanib was effective in blocking the activity of single or
compound PDGFRA D842V mutant kinases. In contrast,
imatinib had no significant activity against these same mu-
tant kinases. A phase II clinical study of crenolanib for treat-
ment of GIST patients with primary or secondary PDGFRA
D842V mutation is currently recruiting patients (Clinical-
Trials.gov Identifier: NCT01243346).
Motesanib (AMG706) is an oral inhibitor of VEGF,
PDGF, and Kit receptors. In a phase 2 multicenter study
of AMG 706 in 102 advanced imatinib-resistant GISTs
[48], the objective response rate was 3%. This included
59% patients who had stable disease. PET scans showed
an objective response rate of 30% and per Choi criteria
of 41%. The median PFS was 16 weeks. The most com-
mon motesanib treatment-related grade 3 adverse events
were hypertension (23%), fatigue (9%), and diarrhea (5%).
PTK787/ZK222584 is another novel, oral selective in-
hibitor of receptor tyrosine kinases (KIT, PDGFRs,
VEGFR-1 and VEGFR-2). In a phase 2 open label study
on PTK787 in GISTs resistant to imatinib [44], 13%
patients achieved PR, 8 (53%) had SD for 3 months or
longer. The clinical benefit rate (PR + SD) was 67%. The
dose of 1,250 mg daily was generally well tolerated.
Novel agents
mTOR inhibitors
Novel approaches to overcome resistance to TKIs in GIST
include targeting multiple levels of the signal transduction
cascade intracellularly by combining agents (Table 3). ThisClinical Trial No. of
patients
Response Reference
/day Phase 1/2 58 PFS 29% [57]
Phase 1/2 15 ORR27% [59]






Phase 2 26 SD 52% [61]
for 2
cles
Phase 3 47 Too toxic [62]
e - 100 mg
eekly
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imatinib with an mTOR inhibitor everolimus. [57]. In this
phase 1/2 trial Schoffski et al. reported stable disease in
36%, PR in 2% and stable disease (SD) in 43% patients who
had progressed after imatinib and sunitinib/other tyrosine
kinase inhibitor. All these patients were treated with ima-
tinib 600 mg/day plus everolimus 2.5 mg/day. Another
phase 1/2 trial showed SD in 8 out of 31 patients in the
trial [58].
Another mTOR inhibitor, sirolimus, as a single agent
has also been reported [59,60]. Richter and co-workers
showed response efficacy (complete response, partial
response or stable disease) in 27% refractory and heavily
pre-treated patients [59]. Piovesan and colleagues reported
anti-tumor activity of sirolimus in combination with TKIs
in 3 patients with PDGFRA-D842V metastatic GIST. Of
these 3 patients, two were progressing on imatinib, while
the third patient was treated with imatinib and sirolimus
upfront [60].Hsp90 inhibitor
Other strategies that are being explored include the in-
hibition of other pathways involving KIT or PDGFRA
oncoproteins, such as the heat shock protein-90 (Hsp90)
chaperon system. By inhibiting Hsp90, preclinical and
early clinical studies have already documented antineo-
plastic effects on resistant GIST both in vitro and in
patients with progressive disease [64,65].
Ganetespib (STA 9090) is a potent, synthetic inhibitor
of Hsp90. It has an improved safety profile relative to
1st-generation Hsp90 inhibitors and has promising sig-
nals of antitumor activity in early clinical studies, in-
cluding one patient with PDGFRA D842V mutant GIST.
Demetri and co-workers [61] enrolled patients with
advanced GIST who failed prior therapy to receive gane-
tespib (200 mg/m2) as a 1 hour IV infusion weekly for
3 weeks of a 28 day cycle. Toxicities reported in more
than 20% patients were grade 1–2 and included diar-
rhea, fatigue, nausea, vomiting, increased alkaline phos-
phatase, headache, insomnia, and abdominal pain. Fifty
two percent (12/23) evaluable patients had stable disease.
However, analysis of client proteins in paired tumor biop-
sies (4 patients) did not show prolonged inhibition of acti-
vated KIT or its downstream pathways. The data suggest
that once-weekly treatment schedule is not optimal for
inhibition of KIT.
Retaspimycin hydrochloride (IPI504, a Hsp90 inhibi-
tor) is another Hsp90 inhibitor [62]. A clinical study was
terminated early due to a higher mortality rate in the
IPI504 arm compared to the placebo arm. IPI504 was
not well tolerated in this patient population. There was
a higher rate of Grade 3 and 4 adverse events, including
LFT abnormalities, in the IPI504 arm.Perifosine
Other drugs that have been tried recently include perifo-
sine [63]. The addition of perifosine to imatinib showed
minimal activity in imatinib-refractory GIST.
Conclusion and future directions
In summary, it is clear that the deeper scientific under-
standing of GIST has led to the development of novel
therapeutic tools such as imatinib and sunitinib to dis-
able the malignant GIST cells. With improved technol-
ogy and rational molecular targeting, this translation of
science into applied therapeutics should continue to
move forward at a very rapid pace. It is foreseeable that
more agents with novel mechanisms of action and tar-
geting different pathways will be studied for GIST
therapy.
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